Inovio Pharmaceuticals NASDAQ: INO at https://www.webull.com/quote/nasdaq-ino was one of the hottest supplies of coronavirus vaccines in 2020. At one point, it traded 10 times as much as the year started, primarily due to the pace at which it pushed the VOCID-19 vaccine candidate through the production process and into phase 1 clinical trials.
Today, Inovio ‘s shares are nowhere near the record they reached in June, and the portfolio seems to be falling again as the global market withdraws from its summer highs. Does that mean that it’s a decent time to purchase Inovio at a fair discount, or is the firm already vulnerable to a broader market slowdown, even as the excitement continues to grow for its coronavirus vaccine candidate, NASDAQ: INO in other words, since June, something has changed about the company’s condition that has strengthened its long-term prospects.
The view that Inovio is likely to be hit badly by the current market correction, since the stock has shown strong volatility even in the absence of news about the firm or its rivals. But, with a joint phase 2/3 clinical trial for INO-4800 expected to begin shortly, it might have a fair chance of bouncing back with similar power. In the last few months, NASDAQ: INO has also made improvements in a variety of key areas that are critical for its strategic place in this race, which suggests that it may be much more worthwhile to purchase the stock during this correction.
Capacity Has Increased
Since submitting its Phase 1 clinical trial results for INO-4800 earlier this year, Inovio has taken ambitious measures to improve its manufacturing capability in expectation of mass production. In September, Thermo Fisher NASDAQ: INOplanned to manufacture approximately 100 million doses of the vaccine in 2021, subject to U.S. regulatory approval. Food and Drug Administration (FDA) at the beginning of the year. The transaction was the third of its kind for Inovio in recent months, and also the biggest, but the company is still searching for additional manufacturing partners to satisfy the projected demand.
And even with those agreements concluded, the production ability of Inovio is still much smaller than that of companies with more advanced candidates such as Moderna (NASDAQ: MRNA), which plans to manufacture between 500 million and 1 billion doses of its nominee, mRNA-1273, in 2021.Thus, even though Inovio’s vaccine is accepted, the firm would also have to do a lot of work to gain production competition with its most likely rivals if it wishes to win a large portion of the market.In July, Inovio increased its phase 1 study cohort by recruiting 80 additional subjects to the initial 40. You can check more stocks like NASDAQ: TSLA at https://www.webull.com/balance-sheet/nasdaq-tsla before investing.
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
